TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39454281

Group type: EXPERIMENTAL
Intervention: IM cohort 1c (25/25/50 mg/m2 MWF)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: IV cohort (25/25/50 mg/m2 MWF)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: IM cohort
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: IV cohort
Number of subjects: 229
Study: 39454458

Group type: EXPERIMENTAL
Intervention: FLEX-D (64% plant protein)
Number of subjects: 19

Group type: COMPARATOR
Intervention: CON-D (36% plant protein)
Number of subjects: 19
Study: 39454617

Group type: EXPERIMENTAL
Intervention: Proximod (doses not specified)
Number of subjects: 34
Study: 39454668

Group type: EXPERIMENTAL
Intervention: Standardized, high-fidelity implementation of the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Standardized, high-fidelity implementation of the M-CHAT-R/F
Number of subjects: 225
Study: 39454735

Group type: EXPERIMENTAL
Intervention: Cam+MDT
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cam
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 39
Study: 39454756

Group type: EXPERIMENTAL
Intervention: Targeted mass-spectrometry-based proteomics
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Proteomics, PCR, and culture combined
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Proteomics
Number of subjects: 57
Study: 39454939

Group type: EXPERIMENTAL
Intervention: FIL-EAS-ic pathway (hospital-at-home care pathway)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Conventional hospitalization pathway
Number of subjects: 454
Study: 39454963

Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Structured clinical management (control)
Number of subjects: 47
Study: 39454998

Group type: EXPERIMENTAL
Intervention: Oronasal CPAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral CPAP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oronasal CPAP in lateral position
Number of subjects: 20
Study: 39455065

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (de novo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (de novo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (continued)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (continued)
Number of subjects: 0
Study: 39455063

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39455493

Group type: EXPERIMENTAL
Intervention: ZXR00V/ZXW150 (VLF group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ZXR00/ZXT150 (UVF group)
Number of subjects: 60
Study: 39455495

Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 174

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 174
Study: 39455572

Group type: EXPERIMENTAL
Intervention: Later Eaters (LE)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Early Eaters (EE)
Number of subjects: 26
Study: 39455575

Group type: EXPERIMENTAL
Intervention: rezpegaldesleukin (REZPEG) 24 µg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rezpegaldesleukin (REZPEG) 10 to 12 µg/kg
Number of subjects: 0
Study: 39455729

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39455971

Group type: EXPERIMENTAL
Intervention: Music group (listened to a 29-minute and 32-second song three days before menstruation and on the first day of menstruation in the third month)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Drawing group (created art for the same duration as the music group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 39455976

Group type: EXPERIMENTAL
Intervention: Pregnant women in third trimester
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 198

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 198
Study: 39455996

Group type: EXPERIMENTAL
Intervention: Single-tufted toothbrush (ST-TB)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush (O-TB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional toothbrush (C-TB)
Number of subjects: 36
Study: 39456048

Group type: EXPERIMENTAL
Intervention: Individualized high PEEP strategy with recruitment maneuvers (RMs)
Number of subjects: 1806

Group type: COMPARATOR
Intervention: Standard low PEEP of 5 cm H2O without recruitment maneuvers (RMs)
Number of subjects: 1806
Study: 39456051

Group type: EXPERIMENTAL
Intervention: Modified Collaborative Assessment (MCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Assessment (Control)
Number of subjects: 0
Study: 39456079

Group type: COMPARATOR
Intervention: Standard of care (healthcare facility-based passive case detection with smear microscopy testing)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Best practice (active case finding and Xpert MTB/RIF Ultra PCR testing followed by household contact investigations)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Novel intervention (active case finding, Xpert MTB/RIF Ultra PCR testing, sputum culture, and M. tuberculosis whole genome sequencing)
Number of subjects: 48
Study: 39456081

Group type: EXPERIMENTAL
Intervention: GAIN Lite added to enhanced usual care (EUC)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) only
Number of subjects: 132
Study: 39456544

Group type: EXPERIMENTAL
Intervention: Empiric intravenous broad-spectrum antibiotics (IVBSA) for at least 48 h with PCT monitoring
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: PCT drop (defined as a reduction of 30% from baseline or a PCT level < 0.25 ng/mL)
Number of subjects: 89
Study: 39457149

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 0
Study: 39457194

Group type: EXPERIMENTAL
Intervention: Music enrichment program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Play date control
Number of subjects: 16
Study: 39457678

Group type: EXPERIMENTAL
Intervention: NP001 (1 mg/kg or 2 mg/kg)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 39458142

Group type: EXPERIMENTAL
Intervention: Preimplantation Genetic Testing for Aneuploidy (PGT-A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard IVF treatment)
Number of subjects: 0
Study: 39458156

Group type: EXPERIMENTAL
Intervention: Virtual Reality treatment
Number of subjects: 0
Study: 39458224

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39458438

Group type: EXPERIMENTAL
Intervention: Caffeine (2.5 mg/kg) administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo administered twice during continuous wakefulness, last treatment 6.5 h before bedtime for recovery night.
Number of subjects: 41
Study: 39460685

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) as adjunctive therapy
Number of subjects: 239
Study: 39460694

Group type: EXPERIMENTAL
Intervention: Atrasentan
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 39460719

Group type: EXPERIMENTAL
Intervention: Subcutaneous ocrelizumab (up to 1200 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Subcutaneous ocrelizumab (920 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Intravenous ocrelizumab (600 mg)
Number of subjects: 135
Study: 39460896

Group type: EXPERIMENTAL
Intervention: UWF-FFA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SS-OCTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CFP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Presence of IRMA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between IRMA and microaneurysms
Number of subjects: 60
Study: 39461270

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks
Number of subjects: 682
Study: 39461299

Group type: EXPERIMENTAL
Intervention: Apraglutide (once-weekly subcutaneous injections)
Number of subjects: 9
Study: 39461302

Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV vaccine
Number of subjects: 18348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18348
Study: 39461733

Group type: EXPERIMENTAL
Intervention: EPO 900 IU/kg (300 IU/kg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EPO 1800 IU/kg (600 IU/kg/day)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: EPO 3600 IU/kg (600 IU/kg/day on presentation and then 1 month later)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study: 39461739

Group type: EXPERIMENTAL
Intervention: Single-capsule BQT containing bismuth, metronidazole, tetracycline, and a proton pump inhibitor (PPI)
Number of subjects: 15682

Group type: EXPERIMENTAL
Intervention: 10-day Single-capsule BQT (ScBQT)
Number of subjects: 15682

Group type: EXPERIMENTAL
Intervention: 14-day BQT using tetracycline plus metronidazole or amoxicillin plus either clarithromycin or metronidazole
Number of subjects: 15682

Group type: EXPERIMENTAL
Intervention: ScBQT scheme
Number of subjects: 15682
Study: 39461792

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g by slow intravenous injection within 15 min of umbilical cord clamping)
Number of subjects: 15068

Group type: COMPARATOR
Intervention: Placebo (matching placebo by slow intravenous injection within 15 min of umbilical cord clamping)
Number of subjects: 15068
Study: 39461860

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (three times per week using a diode laser device, starting on the first day of conditioning and continuing through day 3 post-transplant)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 30
Study: 39461861

Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane delivered via the Sedaconda ACD-S
Number of subjects: 235

Group type: COMPARATOR
Intervention: Intravenous propofol
Number of subjects: 235
Study: 39461864

Group type: EXPERIMENTAL
Intervention: Bosutinib 200 mg QD for 24 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg QD for 24 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: External published data from an edaravone study (MCI186-19)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Registry data from a multicentre ALS cohort study
Number of subjects: 25
Study: 39461869

Group type: EXPERIMENTAL
Intervention: hyperpolarised [1-
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 30
Study: 39461878

Group type: EXPERIMENTAL
Intervention: AdAPT-001 plus a checkpoint inhibitor (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Checkpoint inhibitor (CI)
Number of subjects: 0
Study: 39461901

Group type: EXPERIMENTAL
Intervention: 8 weeks of low-load blood flow restricted resistance training (BFR-RT) 3x/week
Number of subjects: 86

Group type: COMPARATOR
Intervention: Preoperative usual care (CON) involving no exercise
Number of subjects: 86
Study: 39461915

Group type: EXPERIMENTAL
Intervention: IV omadacycline or linezolid
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Oral omadacycline or linezolid
Number of subjects: 1380
Study: 39461964

Group type: EXPERIMENTAL
Intervention: Omnidirectional subthalamic deep brain stimulation (OS)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Directional subthalamic deep brain stimulation (DS)
Number of subjects: 19
Study: 39461973

Group type: EXPERIMENTAL
Intervention: Multi-network gene community detection (MNGCD) approach applied to whole blood samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-network gene community detection (MNGCD) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial infections (Moraxella catarrhalis and Haemophilus influenzae) during acute exacerbations
Number of subjects: 0
Study: 39461975

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 39462030

Group type: EXPERIMENTAL
Intervention: Ringer's Lactate at 15 °C
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ringer's Lactate at 37 °C
Number of subjects: 18
Study: 39462122

Group type: EXPERIMENTAL
Intervention: Children with major alleles for SNP rs864537A > G in CD247 (AA genotype) born March-August
Number of subjects: 6523

Group type: EXPERIMENTAL
Intervention: Interactions with febrile infections between ages 3-6 months
Number of subjects: 6523
Study: 39462179

Group type: EXPERIMENTAL
Intervention: Therapeutic strategies targeting metabolic vulnerabilities in cancer cells
Number of subjects: 0
Study: 39462240

Group type: EXPERIMENTAL
Intervention: Microaxial flow pump (MAFP)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 324
Study: 39462276

Group type: EXPERIMENTAL
Intervention: microaxial flow pump (mAFP)
Number of subjects: 355

Group type: COMPARATOR
Intervention: standard care alone
Number of subjects: 355
Study: 39462308

Group type: EXPERIMENTAL
Intervention: Atacicept
Number of subjects: 0
Study: 39462310

Group type: EXPERIMENTAL
Intervention: Selective Endothelin Receptor Antagonist SC0062
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39462335

Group type: EXPERIMENTAL
Intervention: AgeMatchPLUS intervention (virtual partner-based peer support exercise intervention)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: AgeMatchPLUS intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: AgeMatch (control group)
Number of subjects: 18
Study: 39462341

Group type: EXPERIMENTAL
Intervention: Tailored arm (TA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard arm (SA)
Number of subjects: 42
Study: 39462354

Group type: EXPERIMENTAL
Intervention: Telephone coaching (5 monthly calls from physiotherapist)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Home exercise program alone (control group)
Number of subjects: 99
Study: 39462425

Group type: EXPERIMENTAL
Intervention: Self-confidence
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Executive function
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 395
Study: 39462433

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS at 80% intensity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study: 39462517

Group type: EXPERIMENTAL
Intervention: MBA-P01 (20 U, five treatments over 16 months)
Number of subjects: 0
Study: 39462835

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy + short course of carbon ion radiotherapy (CIRT) followed by surgery and adjuvant chemotherapy
Number of subjects: 0
Study: 39463173

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 or 20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desvenlafaxine (50 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study: 39463187

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 39463194

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction (CLC) with AH Plus sealer (G1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction (CLC) with Endosequence (ES) after standard canal dryness (SD) (G2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Matching single-cone (SC) with ES after standard canal dryness (SD) (G3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Matching single-cone (SC) with ES after partial canal dryness (PD) (G4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-cone obturation technique with HCSBS (ES or CeraSeal) after different dryness protocols (2nd phase)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard dryness protocol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intentional root canal moisture
Number of subjects: 24
Study: 39463195

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 49284

Group type: COMPARATOR
Intervention: Patients with cardiac rupture (CR)
Number of subjects: 49284
Study: 39463395

Group type: EXPERIMENTAL
Intervention: Sublingual microcirculatory assessment on admission
Number of subjects: 44
Study: 39463748

Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg twice daily for 2 years) plus endocrine therapy (ET)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 501
Study: 39464181

Group type: EXPERIMENTAL
Intervention: Low-dose radiation (150 mGy 2x/week for 5 consecutive weeks)
Number of subjects: 15
Study: 39464248

Group type: EXPERIMENTAL
Intervention: Collaborative multidimensional approach for depression (CMAD)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 394
Study: 39464260

Group type: EXPERIMENTAL
Intervention: Guideline-recommended hyperkalaemia management including dietary potassium management
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Practitioners' management decisions
Number of subjects: 1330
Study: 39464680

Group type: EXPERIMENTAL
Intervention: Health behavior (HB) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Paleolithic elimination diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet (SOC)
Number of subjects: 0
Study: 39464932

Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp)
Number of subjects: 185
Study: 39465217

Group type: EXPERIMENTAL
Intervention: Pritumumab (16.2 mg/kg weekly)
Number of subjects: 15
Study: 39465257

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab (200 mg, day 1), anlotinib (10 mg, QD, PO, days 1-14), and platinum-based chemotherapy for 3 cycles, followed by adjuvant sintilimab (200 mg every 3 weeks).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment phase.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Per-protocol set (PP set).
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Event-free survival.
Number of subjects: 45
Study: 39465324

Group type: EXPERIMENTAL
Intervention: PG2 500 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 39465350

Group type: EXPERIMENTAL
Intervention: Filtered-sunlight phototherapy (FSPT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Intensive electric phototherapy (IEPT)
Number of subjects: 192
Study: 39465397

Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Spontaneous improvement
Number of subjects: 73

Group type: COMPARATOR
Intervention: Minimal hepatic encephalopathy (MHE)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Presence of MHE
Number of subjects: 73
Study: 39465531

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg SC every 4 weeks
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Mepolizumab 40 mg SC every 4 weeks (for bodyweight <40 kg)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 514
Study: 39465752

Group type: EXPERIMENTAL
Intervention: Biomimetic oral appliance therapy (BOAT) device
Number of subjects: 17
Study: 39465804

Group type: EXPERIMENTAL
Intervention: Patients with TGA
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Patients with a single TGA event
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study: 39465869

Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 1 (VCI diameter < 1.5 cm, VCI-CI > 50%)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 2 (VCI diameter > 1.5 cm, VCI-CI < 50%)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Lateral sagittal infraclavicular block (LS-ICB) in Group 1
Number of subjects: 2
Study: 39465875

Group type: EXPERIMENTAL
Intervention: Group 27q (27 gauge Quincke needle)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 146
Study: 39465888

Group type: EXPERIMENTAL
Intervention: Lactoferrin (rhLF) at two doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 0
Study: 39466126

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 39466174

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sleep hygiene control
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both CBT-I and Sleep hygiene control
Number of subjects: 67
Study: 39466211

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1105
Study: 39466215

Group type: EXPERIMENTAL
Intervention: PASCAL transcatheter valve repair system
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: PASCAL Precision system
Number of subjects: 1059
Study: 39466236

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone 7), 180 μg, daily for 8 weeks
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo, daily for 8 weeks
Number of subjects: 199
Study: 39466243

Group type: EXPERIMENTAL
Intervention: CP@clinic (intervention)
Number of subjects: 3695

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3695
Study: 39466245

Group type: EXPERIMENTAL
Intervention: Large Language Model (LLM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional resources only
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Large Language Model (LLM) alone
Number of subjects: 50
Study: 39466253

Group type: EXPERIMENTAL
Intervention: Acetazolamide Therapy
Number of subjects: 0
Study: 39466327

Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality game-based training (nIVRGT) plus conventional physiotherapy (40 min + 20 min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional physiotherapy and rehabilitation program (60 min, 3 days a week for 6 weeks)
Number of subjects: 25